Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Solid Tumors: early-phase trial registry
43 of 127 indexed Solid Tumors trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #93 of 28,707 conditions by registered trial count.
127 US clinical trials · 43 currently recruiting · #93 of 28,707 conditions by registered trial count
Solid Tumors: 127 US clinical trials tracked, 43 recruiting.
Solid Tumors is the subject of 127 registered US clinical trials on ClinicalTrials.gov, 43 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 117 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 8 of these trials.
Enrollment posture brief
Registry condition solid-tumors
OPEN 43 | RECR 34% | LATE 4 | EARLY 117 | RANK #93 | SPON 8
Volume-matched condition peers
Nearest open-share peer: Refractory Multiple Myeloma (34% recruiting · 68 trials)
Solid Tumors lists 43 open slots (34% of 127 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Solid Tumors on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Solid Tumors is recruiting below its size-band peers.
43 of 127 indexed trials (33.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Solid Tumors trials is spread across many organizations.
M.D. Anderson Cancer Center accounts for 8 of 127 trials (6.3%). 77 distinct sponsors appear on at least one study for this condition label.
-
Typical Solid Tumors enrolment sits around 70 participants.
Median target enrolment is 70 among the 126 trials that report a genuine target (sentinel values excluded). 72 of those (57.1%) plan for fewer than 100 participants.
-
Solid Tumors research is mostly interventional.
122 interventional and 5 observational studies make up this index (96.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
127 total, page 1 of 3
CIBMTR Research Database
Center for International Blood and Marrow Transplant Research
NCT01166009
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Merck Sharp & Dohme
NCT03486873
PanTheR Registry Trial
RenovoRx
NCT06805461
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Hoffmann-La Roche
NCT04589845
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Incyte Corporation
NCT06179160
Study of INCB123667 in Subjects With Advanced Solid Tumors
Incyte Corporation
NCT05238922
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Apollomics
NCT03175224
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
DualityBio
NCT06953089
A Study of HS-20110 in Participants With Advanced Solid Tumors
Hansoh BioMedical R&D Company
NCT06892379
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Incyte Corporation
NCT05836324
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors
GlaxoSmithKline
NCT06431594
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Arcus Biosciences
NCT05536141
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
ORIC Pharmaceuticals
NCT05315700
Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors
Innovent Biopharmaceutical Technology (Hangzhou) Co.
NCT06963281
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
Shionogi
NCT05101070
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Incyte Corporation
NCT07195916
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Fore Biotherapeutics
NCT05503797
QTX3034 in Patients With KRAS G12D Mutation
Quanta Therapeutics
NCT06227377
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
EMD Serono Research & Development Institute
NCT06710132
Genomic Profiling in Cancer Patients
Memorial Sloan Kettering Cancer Center
NCT01775072
A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
NCT05155332
Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors
Zai Lab (Shanghai) Co.
NCT07374848
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
Exelixis
NCT07123103
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
Daiichi Sankyo
NCT06644755
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
Jacobio Pharmaceuticals Co.
NCT06386146
Study of AUBE00 in Patients With Solid Tumors
Chugai Pharmaceutical
NCT07030959
A Study of ZL-1310 in Participants With Selected Solid Tumors
Zai Lab (Shanghai) Co.
NCT06885281
A Study of GEN1106 in Participants With Solid Tumors
Genmab
NCT07416123
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co.
NCT05490472
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
Tyra Biosciences
NCT06915753
ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC
ORIC Pharmaceuticals
NCT06816992
A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors
Adcentrx Therapeutics
NCT06710379
A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)
Boehringer Ingelheim
NCT05471856
ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
ABL Bio
NCT07158918
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
National Cancer Institute (NCI)
NCT03366116
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
BeOne Medicines
NCT07181681
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
M.D. Anderson Cancer Center
NCT06066424
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
Pfizer
NCT05203172
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
VLP Therapeutics
NCT06736379
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
Spectrum Pharmaceuticals
NCT04570423
Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors
M.D. Anderson Cancer Center
NCT06651593
DPTX3186 in Wnt Pathway Activated Solid Tumors
Dewpoint Therapeutics
NCT07312903
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Valent Technologies
NCT04337177
Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study
Mayo Clinic
NCT02457962
GEN1046 Safety Trial in Patients With Malignant Solid Tumors
Genmab
NCT03917381
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)
Merck Sharp & Dohme
NCT04123366
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Taiho Oncology
NCT02503423
Avelumab Program Rollover Study
EMD Serono Research & Development Institute
NCT03815643
An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech
NCT04250155
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
Pfizer
NCT05262400
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 102 |
| Phase 2 | 15 |
| Phase 3 | 3 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Solid Tumors records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Solid Tumors trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Solid Tumors page
127 registered trials, 43 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 43 Solid Tumors trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Solid Tumors trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Solid Tumors condition card totals 127 registered trials; most-linked intervention Gemcitabine; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.